Date: 2011-12-13
Type of information: Licensing agreement
Compound: PolyTherics’ TheraPEG™ conjugation technology
Company: Polytherics (UK) Nuron Biotech (USA)
Therapeutic area:
Type agreement: licensing
Action mechanism:
Disease:
Details: PolyTherics has announced that Nuron Biotech, Inc, a speciality biologics and vaccines company, has exercised its option to take a licence to PolyTherics’ TheraPEG™ conjugation technology to develop and commercialise a long-acting proprietary human interferon beta-1b (NU400). Nuron’s decision to take an exclusive worldwide licence for the application of TheraPEG™ follows its review of data generated by PolyTherics that demonstrates the efficiency of its conjugation chemistry for site-specific attachment of polyethylene glycol (PEG) to its proprietary human interferon beta-1b and the potency and extended half-life of the PEGylated interferon beta-1b.
Financial terms: PolyTherics will receive an option fee from Nuron and is eligible for further milestone payments and royalties as Nuron progresses NU400 through development.
Latest news: